Effect of home‐based resistance training on chemotherapy relative dose intensity and tolerability in colon cancer: The FORCE randomized control trial

Bette J. Caan,Justin C. Brown,Catherine Lee,Alexandra M. Binder,Erin Weltzien,Michelle C. Ross,Charles P. Quesenberry,Kristin L. Campbell,Elizabeth M. Cespedes Feliciano,Adrienne Castillo,Sara Quinney,Shengping Yang,Jeffrey A. Meyerhardt,Kathryn H. Schmitz
DOI: https://doi.org/10.1002/cncr.35204
IF: 6.9209
2024-01-26
Cancer
Abstract:Background Many patients with colon cancer cannot fully adhere to postoperative chemotherapy due to dose‐limiting toxicities, resulting in lower relative dose intensity (RDI) and potentially compromising overall survival. This study examined whether home‐based resistance training (RT) during adjuvant chemotherapy improves RDI and patient‐reported toxicities versus usual care (UC) in colon cancer patients. Methods Multicenter, randomized control trial (RCT) conducted at community and academic practices. Enrollment of patients receiving postoperative chemotherapy for colon cancer occurred between February 23, 2018, and September 29, 2021; final follow‐up was March 21, 2022. Participants were randomized to RT (n = 90) or UC (n = 91) for the duration of chemotherapy. Participants in the RT group engaged in twice weekly home‐based progressive RT. At the end of the study, UC was given an online exercise program. Results Among 181 randomized patients (mean age, 55.2 [SD, 12.8] years, 95 [52.5%] were men), there were no differences in the mean RDI among those in RT (79% [SD, 19%]) and those in UC (82% [SD, 19%]); (mean difference –0.04 [95% confidence interval (CI), –0.09 to 0.02]). Assignment to RT did not significantly reduce the number of moderate/severe symptoms per week across follow‐up (relative rate: 0.94 [95% CI, 0.72–1.22]). Additionally, time since randomization did not significantly modify the effect of RT on the overall number of symptoms (p = .06). Conclusions Among patients with colon cancer, these results do not support home‐based RT as an adjunct to chemotherapy specifically to improve planned treatment intensity.
oncology
What problem does this paper attempt to address?